ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 312 filers reported holding ROYALTY PHARMA PLC in Q3 2023. The put-call ratio across all filers is 0.16 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,424,309 | -12.0% | 163,018 | -0.3% | 0.02% | -4.8% |
| Q2 2023 | $5,025,898 | -18.8% | 163,497 | -4.8% | 0.02% | -25.0% |
| Q1 2023 | $6,190,242 | +17.0% | 171,808 | +28.4% | 0.03% | +7.7% |
| Q4 2022 | $5,290,781 | -5.0% | 133,811 | -3.5% | 0.03% | -7.1% |
| Q3 2022 | $5,571,000 | -0.4% | 138,670 | +4.2% | 0.03% | +7.7% |
| Q2 2022 | $5,593,000 | +5.4% | 133,042 | -2.3% | 0.03% | +23.8% |
| Q1 2022 | $5,304,000 | -7.4% | 136,141 | -5.0% | 0.02% | +5.0% |
| Q4 2021 | $5,726,000 | +117.2% | 143,361 | +96.5% | 0.02% | +100.0% |
| Q3 2021 | $2,636,000 | -17.3% | 72,953 | -6.2% | 0.01% | -16.7% |
| Q2 2021 | $3,187,000 | -9.4% | 77,751 | -3.6% | 0.01% | -14.3% |
| Q1 2021 | $3,519,000 | +27.6% | 80,686 | +45.1% | 0.01% | +27.3% |
| Q4 2020 | $2,758,000 | – | 55,619 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $294,957,000 | 88.74% |
| Vantage Consulting Group Inc | 8,705,551 | $379,735,000 | 76.23% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $116,930,000 | 72.07% |
| HARVARD MANAGEMENT CO INC | 10,714,284 | $467,357,000 | 26.11% |
| ROBERT WOOD JOHNSON FOUNDATION | 970,151 | $4,231,798,000 | 21.59% |
| Brown University | 381,759 | $16,652,000 | 11.44% |
| Overbrook Management Corp | 771,155 | $33,638,000 | 7.48% |
| SpiderRock Advisors, LLC | 778,800 | $34,236,000 | 4.79% |
| Renaissance Capital LLC | 452,948 | $19,758,000 | 2.93% |
| Lagoda Investment Management, L.P. | 104,835 | $4,573,000 | 2.28% |